The Genetics of "Non-Response" in Adult AML
OBJECTIVES:
- Define a "non-response" signature that will help up-front identification of cases of
intermediate-risk acute myeloid leukemia (AML) destined to fail existing
standard-of-care therapy.
- Identify biological pathways in the "non-response" group that can provide targets for
novel therapeutics.
OUTLINE: DNA and RNA extracted from cryopreserved bone marrow cells and/or blood cells are
analyzed for mutations and gene expression signatures (genome-wide methylation, mRNA and
miRNA expression, and single nucleotide polymorphism (SNP) analysis) by microarray assays.
Observational
N/A
Genetic signature predictive of progression and drug resistance in AML
No
Jerry Radich, MD
Principal Investigator
Fred Hutchinson Cancer Research Center
Unspecified
CDR0000709269
NCT01421862
September 2011
Name | Location |
---|